Infectious Diseases News and Research RSS Feed - Infectious Diseases News and Research

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model. [More]
Cepheid releases Xpert Flu/RSV XC for accurate determination of Flu A, Flu B and RSV infection

Cepheid releases Xpert Flu/RSV XC for accurate determination of Flu A, Flu B and RSV infection

Cepheid announced today the release of Xpert® Flu/RSV XC, an on-demand molecular test for rapid, accurate and reliable determination of Flu A, Flu B, and differentiation of RSV infection. [More]
‘Concerning’ rise in pneumococcus risk factors

‘Concerning’ rise in pneumococcus risk factors

Researchers report that the incidence of Streptococcus pneumoniae infection has fallen significantly in the USA in the past decade but describe a “concerning trend” whereby the baseline health status of those with serious pneumococcal disease has worsened. [More]
New blood test provides fast, accurate diagnosis of tuberculosis in children

New blood test provides fast, accurate diagnosis of tuberculosis in children

A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children. [More]
Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

Wockhardt Limited today announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food & Drug Administration. [More]
Semi-soft vaginal suppository provides drug-delivery vehicle to prevent spread of HIV

Semi-soft vaginal suppository provides drug-delivery vehicle to prevent spread of HIV

A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences. [More]
Gene therapy may offer significant advantages in prevention of botulism exposure

Gene therapy may offer significant advantages in prevention of botulism exposure

The current method to treat acute toxin poisoning is to inject antibodies, commonly produced in animals, to neutralize the toxin. But this method has challenges ranging from safety to difficulties in developing, producing and maintaining the anti-serums in large quantities. [More]
Researchers find method to expand blood stem cells used to treat cancer patients

Researchers find method to expand blood stem cells used to treat cancer patients

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. [More]
Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging results. The vaccines had in fact triggered an antibody response -- now known to be associated with protection in adults -- that was previously unrecognized in the infants studied in the 1990s. [More]
Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. [More]
iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of an series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in West Africa. [More]
NIH to start initial human testing of investigational Ebola vaccine next week

NIH to start initial human testing of investigational Ebola vaccine next week

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. [More]
Researchers develop potential antibody therapy for Sudan ebolavirus

Researchers develop potential antibody therapy for Sudan ebolavirus

Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola. [More]
Microtechnologies to tackle problems of mobility industry and life sciences

Microtechnologies to tackle problems of mobility industry and life sciences

CIC microGUNE, the Co-operative Research Centre into Microtechnologies, is coordinating the microSCALE project which seeks to generate innovative solutions based on microtechnologies to tackle the problems of the mobility industry and life sciences, among others. [More]
University of Liverpool researchers identify pathogens that pose greater risk to people in Europe

University of Liverpool researchers identify pathogens that pose greater risk to people in Europe

The pathogens posing the greatest risk to Europe based upon a proxy for impact have been identified by University of Liverpool researchers using a 'big data' approach to scientific research. [More]
Experts call for action to prevent health risks associated with climate change

Experts call for action to prevent health risks associated with climate change

Previously unrecognized health benefits could be realized from fast action to reduce climate change and its consequences. For example, changes in energy and transport policies could save millions of lives annually from diseases caused by high levels of air pollution. The right energy and transport policies could also reduce the burden of disease associated with physical inactivity and traffic injury. [More]
BD announces winners of 2014 "Innovations in Care" awards

BD announces winners of 2014 "Innovations in Care" awards

BD (Becton, Dickinson and Company), a leading global medical technology company – together with Direct Relief and the National Association of Community Health Centers – has announced the winners of the 2014 "Innovations in Care" awards to seven community health centers as part of the BD Helping Build Healthy CommunitiesSM initiative. [More]
UAB scientist receives R01 grant to study transmission of deadly bacteria from mothers to infants

UAB scientist receives R01 grant to study transmission of deadly bacteria from mothers to infants

New research from the University of Alabama at Birmingham School of Optometry will study the transmission of a bacteria that up to 40 percent of healthy women carry, which becomes deadly when passed on to infants during birth. [More]
Three commonly used NSAIDs affect cell membranes, produce unwanted side effects

Three commonly used NSAIDs affect cell membranes, produce unwanted side effects

Researchers have discovered that three commonly used nonsteroidal anti-inflammatory drugs, or NSAIDs, alter the activity of enzymes within cell membranes. Their finding suggests that, if taken at higher-than-approved doses and/or for long periods of time, these prescription-level NSAIDs and other drugs that affect the membrane may produce wide-ranging and unwanted side effects. [More]